JPH053848B2 - - Google Patents
Info
- Publication number
- JPH053848B2 JPH053848B2 JP686987A JP686987A JPH053848B2 JP H053848 B2 JPH053848 B2 JP H053848B2 JP 686987 A JP686987 A JP 686987A JP 686987 A JP686987 A JP 686987A JP H053848 B2 JPH053848 B2 JP H053848B2
- Authority
- JP
- Japan
- Prior art keywords
- aspoxycillin
- trihydrate
- injection
- preparation
- vial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 claims description 24
- 150000004684 trihydrates Chemical class 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 ornithine Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP686987A JPS63174928A (ja) | 1987-01-14 | 1987-01-14 | 注射用製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP686987A JPS63174928A (ja) | 1987-01-14 | 1987-01-14 | 注射用製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63174928A JPS63174928A (ja) | 1988-07-19 |
| JPH053848B2 true JPH053848B2 (ar) | 1993-01-18 |
Family
ID=11650239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP686987A Granted JPS63174928A (ja) | 1987-01-14 | 1987-01-14 | 注射用製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63174928A (ar) |
-
1987
- 1987-01-14 JP JP686987A patent/JPS63174928A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63174928A (ja) | 1988-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR840001776B1 (ko) | 세프타지딤 펜타하이드레이트의 제조방법 | |
| US4942166A (en) | Crystalline purine compounds | |
| US5200558A (en) | S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset-hastened enhanced analgesics | |
| JPH08505645A (ja) | 結晶性ペニシリン誘導体並びにその製造及び使用 | |
| BG63821B1 (bg) | Фармацевтичен състав на стабилизиран карбапенемовантибиотик и метод за получаване | |
| KR960003327B1 (ko) | 디클로페낙과 환상 유기염기와의 염 및 이를 함유한 약학적 조성물 | |
| PT89474A (pt) | Processo para a preparacao de sais de cefalosporina e de composicoes injectaveis que os contem | |
| CA2434927C (en) | Pharmaceutical compositions with antibiotic activity | |
| CA1215647A (en) | Pharmaceutical compositions | |
| EP1618894B1 (en) | Composition for injection | |
| US4772589A (en) | Etoposide solution in NMP | |
| FI89454B (fi) | Foerfarande foer framstaellning av ett lyofiliserat antibakteriellt preparat | |
| JPH053848B2 (ar) | ||
| US4235900A (en) | Cephradine compositions | |
| CA1170571A (en) | Pharmaceutical compositions | |
| JP2761005B2 (ja) | セファロスポリン含有注射用組成物 | |
| US6060498A (en) | Composition containing antitumor agent | |
| US6784315B2 (en) | Stilbene derivative crystal and method for producing the same | |
| EP0381915B1 (en) | Process for preparing alkali metal salts of 3,7-substituted 7-aminocephalosporanic acid derivatives. | |
| CA1275932C (en) | Solution containing luprostiol | |
| PT91383B (pt) | Processo para a preparacao do acido (5r,6s)-2-carbamoiloximetil-6-{(1r)-hidroxi-etil}-2-penem-3-carboxilico sob a forma cristalina e de composicoes farmaceuticas que o contem | |
| JP3178726B2 (ja) | 抗菌剤組成物 | |
| KR830000525B1 (ko) | 주사용 아세틸 살리실레이트 분말제의 안정화 방법 | |
| KR19990001504A (ko) | 세프타지딤의 유기알카리염을 함유하는 주사제 | |
| JPH04247031A (ja) | 抗菌性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |